RT Journal Article
SR Electronic
T1 Twin-based Mendelian Randomization Analyses Highlight Smoking’s Effects on Blood DNA Methylation, with Putative Reverse Causation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.19.24309184
DO 10.1101/2024.06.19.24309184
A1 Singh, Madhurbain
A1 Dolan, Conor V.
A1 Lapato, Dana M.
A1 Hottenga, Jouke-Jan
A1 Pool, René
A1 Verhulst, Brad
A1 Boomsma, Dorret I.
A1 Breeze, Charles E.
A1 de Geus, Eco J. C.
A1 Hemani, Gibran
A1 Min, Josine L.
A1 Peterson, Roseann E.
A1 Maes, Hermine H. M.
A1 van Dongen, Jenny
A1 Neale, Michael C.
YR 2024
UL http://medrxiv.org/content/early/2024/06/20/2024.06.19.24309184.abstract
AB Epigenome-wide association studies (EWAS) aim to identify differentially methylated loci associated with complex traits and disorders. EWAS of cigarette smoking shows some of the most widespread DNA methylation (DNAm) associations in blood. However, traditional EWAS cannot differentiate between causation and confounding, leading to ambiguity in etiological interpretations. Here, we apply an integrated approach combining Mendelian Randomization and twin-based Direction-of-Causation analyses (MR-DoC) to examine causality underlying smoking-associated blood DNAm changes in the Netherlands Twin Register (N=2577). Evidence across models suggests that current smoking’s causal effects on DNAm likely drive many of the previous EWAS findings, implicating functional pathways relevant to several adverse health outcomes of smoking, including hemopoiesis, cell- and neuro-development, and immune regulation. Additionally, we find evidence of potential reverse causal influences at some DNAm sites, with 17 of these sites enriched for gene regulatory functional elements in the brain. The top three sites with evidence of DNAm’s effects on smoking annotate to genes involved in G protein-coupled receptor signaling (GNG7, RGS3) and innate immune response (SLC15A4), elucidating potential biological risk factors for smoking. This study highlights the utility of integrating genotypic and DNAm measures in twin cohorts to clarify the causal relationships between health behaviors and blood DNAm.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding from the U.S. National Institute on Drug Abuse grant R01DA049867, the Netherlands Organization for Scientific Research (NWO): Biobanking and Biomolecular Research Infrastructure (BBMRI-NL, NWO 184.033.111) and the BBRMI-NL-financed BIOS Consortium (NWO 184.021.007), NWO Large Scale infrastructures X-Omics (184.034.019), Genotype/phenotype database for behavior genetic and genetic epidemiological studies (ZonMw Middelgroot 911-09-032); Netherlands Twin Registry Repository: researching the interplay between genome and environment (NWO-Groot 480-15-001/674); the Avera Institute, Sioux Falls (USA), and the U.S. National Institutes of Health (NIH R01HD042157-01A1, R01MH081802, R01MH125938, and Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995). DML is supported by the NIH K01MH131847. DIB acknowledges the Royal Netherlands Academy of Science Professor Award (PAH/6635). JLM and GH are supported by the UK Medical Research Council (MRC) Integrative Epidemiology Unit at the University of Bristol (MC_UU_00011/1, MC_UU_00011/5).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We analyzed data from the Netherlands Twin Register, which is approved by the Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Centre, Amsterdam, an Institutional Review Board certified by the U.S. Office of Human Research Protections (IRB number IRB00002991 under Federal-wide Assurance-FWA00017598; IRB/institute codes, NTR 98-222, 2003-180, 2008-244).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData from the Netherlands Twin Register (NTR) may be accessed for research purposes by submitting a data-sharing request. Further information about NTR data access is available at https://ntr-data-request.psy.vu.nl/. Results of all MR-DoC models fitted in this study are available as Supplementary Data.